Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance, with significant sales growth across key segments and raised guidance for 2025. Despite a slight decrease in profit margins, the overall outlook remains positive, supported by new product launches and strategic investments. The Q&A section highlights management's confidence in sustained growth, although some concerns about FX impacts and litigation charges were noted. The positive physician feedback and strategic initiatives further bolster the sentiment, suggesting a positive stock price movement over the next two weeks.
Key Financial Performance
Total Sales Sales in the quarter grew 12.6% to $1.55 billion year-over-year, driven by a comprehensive portfolio across multiple therapeutic areas and an established global presence.
TAVR Global Sales Third quarter global sales of $1.15 billion increased 10.6% year-over-year, driven by renewed focus on treating aortic stenosis patients, guideline updates, and expanded education.
TMTT Sales Third quarter sales of $144 million increased 53% year-over-year, fueled by strong performance of PASCAL and EVOQUE, and supported by new ESC/EACTS guidelines.
Surgical Product Sales Third quarter global sales of $258 million increased 5.6% year-over-year, driven by adoption of RESILIA therapy and positive procedure growth for patients best treated surgically.
Adjusted Gross Profit Margin Adjusted gross profit margin was 77.9%, down from 80.7% year-over-year, primarily due to foreign exchange and operational expenses.
Adjusted Operating Profit Margin Adjusted operating profit margin was 27.5%, benefiting from better-than-expected sales performance and deferred spending to Q4.
R&D Expense R&D expense was $281 million, representing 18.1% of sales, compared to 18.7% in the prior year, reflecting strategic prioritization of investments in structural heart portfolio.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SAPIEN, EVOQUE, and SAPIEN M3: Highlighted as groundbreaking transcatheter therapies with significant clinical data presented at TCT. SAPIEN platform has over 15 years of clinical trials, involving 10,000+ patients and 1.2 million treated globally. Proven durability and performance at 7 and 10 years.
PASCAL, EVOQUE, and SAPIEN M3: Differentiated portfolio for mitral and tricuspid diseases. PASCAL and EVOQUE showed strong growth, with EVOQUE demonstrating consistent tricuspid regurgitation elimination. SAPIEN M3 showed excellent outcomes in critically sick patients unsuitable for TEER and surgery.
RESILIA portfolio: Achieved double-digit growth, driven by INSPIRIS, KONECT, and MITRIS therapies. Expanded access globally, including European approval for KONECT.
TAVR (Transcatheter Aortic Valve Replacement): Global sales of $1.15 billion in Q3, up 10.6% YoY. Growth driven by new evidence, guideline updates, and expanded education. U.S. and OUS markets showed strong growth, with Europe benefiting from competitor exit and Japan showing recovery.
TMTT (Transcatheter Mitral and Tricuspid Therapies): Q3 sales of $144 million, up 53% YoY. Strong global adoption of PASCAL and EVOQUE, supported by new ESC/EACTS guidelines. Expected to grow to $2 billion by 2030.
Sales Growth: Q3 sales grew 12.6% to $1.55 billion. Full-year sales growth guidance raised to the high end of 9%-10% range. EPS guidance also raised to $2.56-$2.62.
Gross Profit Margin: Adjusted gross profit margin for Q3 was 77.9%, in line with expectations. Full-year margin expected to be 78%-79%.
R&D Investments: R&D expense was $281 million in Q3, reflecting strategic prioritization of structural heart portfolio.
Expansion into Heart Failure and Aortic Regurgitation: Leveraging structural heart expertise to extend into these areas as next-generation growth contributors.
Guideline and Policy Changes: New guidelines and policies for valvular heart disease and severe aortic stenosis are expected to drive multiyear growth opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Policy Changes: The company anticipates potential catalysts from new U.S. National Coverage Determination (NCD) and evolving guidelines, but these changes could also introduce uncertainties or delays in adoption.
Foreign Exchange Impact: The weakening dollar has negatively impacted gross profit margins and could continue to pose challenges to financial performance.
Supply Chain and Operational Costs: Operational expenses and foreign exchange pressures have impacted gross profit margins, and there is a risk of further cost increases.
Market Competition: While the company has a strong competitive position, the exit of a competitor in Europe has led to market rebalancing, which could introduce uncertainties in market dynamics.
Product Adoption and Market Penetration: The company is focusing on increasing therapy adoption in underpenetrated regions, but this effort may face challenges due to varying regional healthcare infrastructure and patient access.
R&D and Investment Timing: The company has deferred certain spending to Q4, which could impact the timing of strategic initiatives and operational execution.
Economic and Market Conditions: Economic uncertainties and market conditions could impact the company's ability to achieve its growth targets, particularly in regions with slower adoption rates.
Leadership Transition: The planned CFO transition by mid-2026 introduces potential risks related to leadership continuity and strategic execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Sales Growth Guidance: The company has raised its full year sales growth guidance to the high end of the previous 9% to 10% range.
Earnings Per Share (EPS) Guidance: EPS guidance range has been raised to between $2.56 and $2.62.
2026 and Beyond Growth Expectations: The company expects sustainable top-line growth driven by multiple growth drivers, with sales and profitability growth in line with prior commitments.
TAVR Sales Growth Guidance: Full year TAVR guidance has been raised to 7% to 8% from the previous 6% to 7% range. Long-term growth is expected to be mid- to high single digits, supported by proven long-term evidence, new indications, guideline and policy changes, and the potential to serve patients with moderate AS.
TMTT Sales Guidance: The company remains on track to achieve full year TMTT sales guidance of $530 million to $550 million. TMTT is expected to grow to an estimated $2 billion by 2030.
Surgical Sales Guidance: Full year 2025 surgical global sales are expected to grow in the mid-single digits, driven by RESILIA portfolio adoption and growth in heart valve procedures.
Fourth Quarter Guidance: Total company sales for Q4 are projected to be $1.51 billion to $1.59 billion, with adjusted EPS of $0.58 to $0.64.
Long-Term Financial Goals: The company remains confident in delivering long-term financial goals for each business unit, as outlined in the prior year's investor conference.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: The company continues to generate dividends on the RESILIA portfolio and expand access globally.
Share Repurchase Program: The Board of Directors has increased the company's repurchase authorization, resulting in approximately $2 billion remaining under the current authorization. Average diluted shares outstanding during the quarter were 586 million. Based on year-to-date share repurchases of over $800 million, including the previously announced accelerated share repurchase of $500 million, the company now expects lower full year shares outstanding to be between 585 million to 590 million versus original guidance of 585 million to 595 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What contributed to the 10.6% TAVR growth in Q3?
A:The growth was driven by several factors, including a renewed focus on TAVR due to new data and guidelines, reduced summer seasonality impact, and strong performance in Q3. However, management does not consider Q3 results as the new normal for TAVR.
Q:What feedback was received from physicians at TCT regarding the 7-year and 10-year TAVR data?
A:Physicians were very positive about the data, which reassured them about the durability of TAVR valves, particularly the SAPIEN 3 platform. The data supports earlier treatment in the disease progression pathway and highlights economic benefits of timely intervention.
Q:What is the confidence level in achieving 10% organic growth and margin expansion next year?
A:Management expressed confidence in achieving 10% organic growth and 50-100 basis points margin expansion, citing the strong performance of the SAPIEN platform and the momentum seen in Q3. However, the impact of FX on margins will be clarified in December.
Q:What is the status of the JenaValve deal and SAPIEN X4 pivotal data?
A:Management is pursuing regulatory approval for JenaValve, with a ruling expected in Q1. The SAPIEN X4 pivotal trial (ALLIANCE trial) is in the follow-up phase, with completion expected at the end of 2024.
Q:What is the significance of the PREVUE-VALVE study and its impact on TAVR and surgical valve businesses?
A:The study validates assumptions about the size of the aortic stenosis (AS) market and highlights the prevalence of valvular heart disease. It is expected to increase awareness, referrals, and adoption of TAVR and surgical valve treatments.
Q:How does the M3 launch compare to the EVOQUE launch?
A:The M3 launch is focused on a controlled, high-value model with physician training and excellent outcomes. While the EVOQUE launch provides some insights, the M3 launch is tailored to mitral patients unsuitable for TEER and surgery.
Q:Why does management believe Q3 TAVR performance is not sustainable?
A:Management attributes Q3 performance to a renewed focus on TAVR and reduced summer seasonality but does not see evidence of asymptomatic patients driving growth. They believe the major catalysts for TAVR growth are still ahead.
Q:What was the litigation charge mentioned in the earnings call?
A:The litigation charge was related to reserves taken for ongoing litigation activities, which are common in the medical technology industry. Details were reflected in the GAAP P&L.
Q:What is the outlook for tricuspid and mitral valve therapies?
A:The tricuspid valve therapy is experiencing strong growth, supported by positive real-world data and a comprehensive portfolio. The mitral valve therapy (M3) is in a controlled launch phase, focusing on high-value outcomes and training.
Q:What initiatives are being undertaken to improve efficiency in the cath lab?
A:Initiatives include the Benchmark program for improving cath lab efficiencies, partnerships with AI companies for patient screening, direct-to-patient marketing, and education programs to enhance referral and adoption rates.
Q:What is the outlook for R&D spending?
A:R&D spending will continue to be a priority for driving top-line growth, but management plans to ensure that top-line growth outpaces R&D spending growth. R&D as a percentage of sales is expected to trend downward.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the impact of FX on margins, stating that they would address it in December. Additionally, they did not provide clear evidence of asymptomatic patients driving Q3 TAVR growth, citing a lack of coverage for the indication.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO role
EACTS guideline
ENCIRCLE trial
ESC EACTS
EVOQUE SAPIEN
England Journal
Journal Medicine
New England
PARTNER III
PASCAL EVOQUE
SAPIEN year
SAVR
TEER
TMTT
adoption SAPIEN
adviser
confidence
control arm
durability
elimination
expertise heart
focus
generation contributor
guideline update
mortality
pacemaker rate
partner
potential
process successor
publication
region
replacement therapy
result TAVR
spending
stenosis
transition
treatment patient
EW Transcript
Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
EW Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
